At the news
? BULLISHIMPACT 7/10 8-K filed Nov 9, 2026 at 16:08 ET
Larimar Therapeutics completed its rolling BLA submission to the FDA seeking accelerated approval of nomlabofusp for Friedreich's ataxia, a major regulatory milestone for a clinical-stage biotech with a $245M market cap. The company also disclosed a preliminary cash balance of $128.7M as of September 30, 2026, down from $200.4M at March 31, 2026, with a projected cash runway into late Q2 2027.
- Completed rolling BLA submission to FDA seeking accelerated approval of nomlabofusp for Friedreich's ataxia on November 9, 2026
- FDA previously confirmed existing data package appears capable of supporting submission and review of a BLA seeking accelerated approval
- FDA reaffirmed willingness to consider skin FXN as a novel surrogate endpoint
- Preliminary cash, cash equivalents and marketable securities of $128.7M as of September 30, 2026, down from $200.4M at March 31, 2026
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access